Today’s Research Reports on Trending Tickers: Pfizer and Novartis
U.S. equities plunged on Thursday as worries over global growth weighed on the broader market and investors continued to digest the minutes from the Federal Reserve. The Dow Jones Industrial Average shed 1.27 percent to close at 25,379.45, while the S&P 500 Index dropped 1.44 percent to close at 2,768.78. The Nasdaq Composite Index declined 2.06 percent to close at 7,485.14.
"To me, this reflects a lack of trust in the Federal Reserve," said president at Icon Funds, Craig Callahan. "The market fears the Fed will over-tighten," he added.
RDI Initiates Coverage on:
Pfizer’s stock moved 1.28% lower Thursday, to close the day at $44.00. The stock recorded a trading volume of 21,345,724 shares, which was above its three months average volume of 20,659,512 shares. In the last year, Pfizer’s shares have traded in a range of 33.20 – 45.81. The share price has gained 32.53% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $43.36 is above its 200-day moving average of $38.84. Shares of the company are trading at a Price to Earnings ratio of 11.75. Shares of Pfizer have gained roughly 1.13 percent in the past month and are up 21.48 percent year-to-date.
Access RDI’s Pfizer Inc. Research Report at:
On Thursday, shares of Novartis recorded a trading volume of 5,484,768 shares, which was above the three months average volume of 1,835,761 shares. The stock ended the day 1.13% higher at $86.24. The share price has fallen 8.44% from its 52 week high with a 52 week trading range of 72.30 – 94.19. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $84.61 is above its 200-day moving average of $80.23. Shares of the company are trading at a Price to Earnings ratio of 14.66. Shares of Novartis have gained roughly 1.42 percent in the past month and are up 2.72 percent year-to-date.
Access RDI’s Novartis AG Research Report at:
Our Actionable Research on Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.